Education
About Us
Working with TipRanks
Follow Us
Inmune Bio (INMB)
:INMB
Total Valuation
Inmune Bio has a market cap or net worth of $71.51M. The enterprise value is $156.71M.
Market Cap$71.51M
Enterprise Value$156.71M
Share Statistics
Inmune Bio has 26,585,258 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding26,585,258
Owned by Insiders17.01%
Owned by Institutions0.61%
Financial Efficiency
Inmune Bio’s return on equity (ROE) is -1.31 and return on invested capital (ROIC) is -131.26%.
Return on Equity (ROE)-1.31
Return on Assets (ROA)-1.06
Return on Invested Capital (ROIC)-131.26%
Return on Capital Employed (ROCE)-1.32
Revenue Per Employee1.08K
Profits Per Employee-3.24M
Employee Count13
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inmune Bio is ―. Inmune Bio’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value2.90
Price to FCF0.00
Price to Operating Cash Flow-1.41
PEG Ratio―
Income Statement
In the last 12 months, Inmune Bio had revenue of 14.00K and earned -42.08M in profits. Earnings per share was -2.08.
Revenue14.00K
Gross Profit14.00K
Operating Income-42.63M
Pretax Income-42.08M
Net Income-42.08M
EBITDA-42.08M
Earnings Per Share (EPS)-2.08
Cash Flow
In the last 12 months, operating cash flow was -32.71M and capital expenditures 0.00, giving a free cash flow of -32.71M billion.
Operating Cash Flow-32.71M
Free Cash Flow-32.71M
Free Cash Flow per Share-1.23
Dividends & Yields
Inmune Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.95
52-Week Price Change-61.84%
50-Day Moving Average4.77
200-Day Moving Average6.35
Relative Strength Index (RSI)41.43
Average Volume (3m)6.21M
Important Dates
Inmune Bio upcoming earnings date is Aug 7, 2025, TBA (Confirmed).
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Inmune Bio as a current ratio of 3.14, with Debt / Equity ratio of 1.17%
Current Ratio3.14
Quick Ratio3.14
Debt to Market Cap<0.01
Net Debt to EBITDA0.49
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Inmune Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Inmune Bio EV to EBITDA ratio is -1.73, with an EV/FCF ratio of -2.18.
EV to Sales5.19K
EV to EBITDA-1.73
EV to Free Cash Flow-2.18
EV to Operating Cash Flow-2.18
Balance Sheet
Inmune Bio has $19.34M in cash and marketable securities with $347.00K in debt, giving a net cash position of -$18.99M billion.
Cash & Marketable Securities$19.34M
Total Debt$347.00K
Net Cash-$18.99M
Net Cash Per Share-$0.71
Tangible Book Value Per Share$0.78
Margins
Gross margin is 100.00%, with operating margin of -304535.71%, and net profit margin of -300585.71%.
Gross Margin100.00%
Operating Margin-304535.71%
Pretax Margin-300585.71%
Net Profit Margin-300585.71%
EBITDA Margin-300585.71%
EBIT Margin-304535.71%
Analyst Forecast
The average price target for Inmune Bio is $7.72, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$7.72
Price Target Upside169.93% Upside
Analyst ConsensusHold
Analyst Count6
Revenue Growth Forecast-90.97%
EPS Growth Forecast-27.47%